Shire PLC (SHP) Insider Dominic Blakemore Acquires 133 Shares of Stock
Shire PLC (LON:SHP) insider Dominic Blakemore purchased 133 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The shares were purchased at an average price of GBX 5,010 ($65.40) per share, for a total transaction of £6,663.30 ($8,697.69).
Shares of Shire PLC (LON:SHP) opened at 4997.602539 on Monday. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00. The company’s 50 day moving average price is GBX 4,983.22 and its 200 day moving average price is GBX 4,511.67. The stock’s market cap is GBX 34.12 billion.
The firm also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be given a GBX 3.51 ($0.05) dividend. The ex-dividend date is Thursday, September 8th. This represents a dividend yield of 0.07%.
SHP has been the topic of several research reports. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research report on Monday, September 19th. HSBC downgraded Shire PLC to a “hold” rating and dropped their target price for the stock from GBX 5,400 ($70.49) to GBX 5,250 ($68.53) in a report on Monday, September 26th. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a report on Friday, July 22nd. Goldman Sachs Group Inc. reissued a “buy” rating and issued a GBX 6,300 ($82.23) target price on shares of Shire PLC in a report on Tuesday, July 12th. Finally, BNP Paribas reissued an “outperform” rating and issued a GBX 5,700 ($74.40) target price on shares of Shire PLC in a report on Tuesday, July 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of GBX 5,828 ($76.07).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.